News
Business Overview
Business Description
PolarisQB is utilizing Quantum Computing, Artificial Intelligence, Machine Learning and Personalized Medicine to Revolutionize Drug Design. By compressing the lead time for pre-clinical drug candidates from 5 years to 4 months, we will produce up to 100 drug blueprints per year, enabling real time adaptability within the precision medicine market. Using these methodologies, Polaris will build an IP portfolio of drug assets to license, sell, or develop internally.
Operating Status
Active
Founded
December 2019
Total Employees
15
Sectors
Sub Sectors
Offering Type
Software
Business Model
B2B
Business Stage
Funding
Total Funding
$2,100,000
Last Funding Round
Seed
Valuation
Funding Rounds
Investors
AI Technology Stack
AI Description
Polarisqb has employed artificial intelligence in its Tachyontm quantum drug design system, programming the platform to learn from each computational chemistry run that it completes. By doing so, the system is able to create its own inferences about relationships and characteristics of the molecules in the massive chemical libraries within which it operates. This means that as the system continues to perform molecular analysis in the protein targeting process, it will become faster and better able to simulate complex computational chemistry with each run. Combining the power of Artificial Intelligence with the advantage provided by a quantum computing system allows Polarisqb to revolutionize the drug discovery process, cutting the timelines for computer aided drug designs by up to ten times. As the Tachyontm system continues to learn from the simulations it runs, it can provide additional information about molecules that may be able to solve problems that are even outside of the scope of a desired target during a particular run.
AI Technology
Machine Learning
AI Employees
1
